VALBIOTIS
11.1.2021 07:37:36 CET | Business Wire | Press release
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its participation in the prestigious 'J.P. Morgan Healthcare' annual conference, taking place from 11 to 14 January 2021, in virtual format.
Sébastien Peltier, CEO of VALBIOTIS, and Jocelyn Pineau, CFO, are taking part in this key event for biotechnology and pharmaceutical companies. They will use this opportunity to raise the profile of VALBIOTIS, a company specializing in the prevention of metabolic diseases, with over 10,000 international specialists from the healthcare industry who meet by invitation each year.
Founded in 1983, this annual event has become the most important international conference in the sector. It enables emerging and innovative companies with high growth potential to establish and maintain contacts within the industry and with international investors specialized in the field of health and biotechnologies. VALBIOTIS is one of the French companies invited to this major event.
At the same time, VALBIOTIS is also participating in the H.C. WAINWRIGHT BioConnect 2021 conference. This satellite event dedicated to biotechnologies brings together 350 companies that will be presented to international investors in the sector from January 11 to 14, 2021.
VALBIOTIS will make this most of this opportunity to present its development strategy, as well as the decisive steps already taken in 2020 (including the Partnership with Nestlé Health Science and the launch of the REVERSE-IT study) and the outlook for 2021. This new year looks just as promising, with the launch of the HEART Phase II clinical study for TOTUM-70 (reduction of LDL hypercholesterolemia) initiated in the second half of 2020 and the launch of the Phase II clinical study for TOTUM-854 (reduction of blood pressure).
Download the slideshow of meetings on the Company website, in the Documentation section dedicated to investors: www.valbiotis.com/en/documents/
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com
.
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-SME 150
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com
).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005006/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adaptive announces strategic investment from HSBC and Citi to fuel capital markets technology innovation5.3.2026 14:01:00 CET | Press release
Investment capitalizes on significant technological shifts in capital markets driven by cloud, open-source and AIFunding to scale Adaptive’s development of next-gen cloud-enabled front office solutions, centered around its Aeron® technology Adaptive, a leader in custom trading technology solutions, announces it has secured strategic investment from two prominent global financial institutions, Citi and HSBC. This funding is set to significantly accelerate Adaptive’s growth and product innovation roadmap. The strategic backing from HSBC and Citi underscores the collaboration between Adaptive and two of the world’s largest financial institutions on strategic initiatives to reshape capital markets technology. It will enable Adaptive to capitalize on significant technological disruption and meet the growing demand for client‑owned, differentiated and bespoke trading technology. Centered around Adaptive’s suite of Aeron®products, the funding allows the company to scale its delivery of high-p
CPAC Systems AB Chooses RideController, Inc. Accelerating Intelligent Boat Innovation5.3.2026 14:00:00 CET | Press release
CPAC Systems AB today announces a partnership between its premium marine integration platform Marivue and RideController, Inc. RideController becomes an Integrated Experience Partner within the Marivue ecosystem, advancing integration, automation, and user experience for next generation watersports and recreational boats. The partnership combines Marivue’s digital dashboard, integrated boat architecture, and Horizon cloud platform with RideController’s next generation power distribution and LED control systems. Together, the companies will deliver a fully integrated electrical and lighting experience for watersports and premium recreational vessels. Rather than treating switching and lighting as separate subsystems, the collaboration establishes a cohesive digital and electrical backbone. RideController’s distributed solid state power and advanced LED control technology will integrate into Marivue products, enabling unified control, diagnostics, and mode based automation. “RideControll
LabVantage Solutions Introduces LabVantage CORTEX, Advancing Its LIMS Platform for AI-Driven Laboratory Operations5.3.2026 13:30:00 CET | Press release
—Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data —— Learn More from LabVantage Leadership at Pittcon 2026 — LabVantage Solutions, Inc., a global provider of laboratory informatics solutions and services, today announced the launch of LabVantage CORTEX, a next-generation artificial intelligence (AI), analytics, and automation platform. The launch represents a strategic evolution of the company’s laboratory informatics portfolio, integrating advanced AI and smarter automation into the core LabVantage LIMS experience to help laboratories operate with greater accuracy, efficiency, and confidence. LabVantage CORTEX is built to support the growing demand for intelligent, automated laboratory environments across industries, including pharma and biotech, food and beverage, oil and gas, forensics, and more. LabVantage CORTEX provides a customer-centric AI analytics and automation ecosystem t
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom